BioSpace News Archive

IDEXX Innovative Diagnostic and Software Solutions Provide Workflow Efficiency and Faster, More Confident Clinical Decisions

IDEXX Laboratories, Inc. announced today a series of product and service enhancements that enable veterinary practices to be more efficient, while managing increasing patient volumes.

January 13, 2022
·
5 min read
Business

Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets

Scorpion Therapeutics, Inc. today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.

January 13, 2022
·
3 min read
Business

Forma Therapeutics Elects Esteemed Clinician and Industry Veteran Arturo Molina, M.D., to Board of Directors and R&D Committee

Forma Therapeutics Holdings, Inc. today announced that Arturo Molina, M.D., M.S., F.A.C.P., has been elected to serve on the company’s board of directors and R&D committee.

January 13, 2022
·
5 min read
Business

TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma

AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US.

January 13, 2022
·
14 min read
BioCapital

AstraZeneca Aims to Redefine Liver, Biliary Tract and Prostate Cancer Treatment With Practice-Changing IMFINZI® (durvalumab) and LYNPARZA® (olaparib) Data at ASCO GI and GU

AstraZeneca will present new data in liver, biliary tract and prostate cancers illustrating its ambition to revolutionize cancer care at the 2022 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) and the 2022 ASCO Genitourinary Cancers Symposium (ASCO GU).

January 13, 2022
·
25 min read
Drug Development

Prior to Phase III Psoriasis Data Release Can Fite Reports that Piclidenoson Destroys Pathological Skin Cells in vitro

Can-Fite BioPharma Ltd. today announced that pre-clinical studies with skin cells, modeling psoriasis in humans, show that Piclidenoson, the Company’s drug candidate for the treatment of psoriasis, destroys pathological skin cells.

January 13, 2022
·
6 min read
Achilles Therapeutics Provides Business Update and Outlook for 2022

Achilles Therapeutics plc today announces a business update and reflects on recent progress with its pioneering, personalized T cell therapy programs targeting clonal neoantigens known as cNeT.

January 13, 2022
·
5 min read
Business

BridgeBio Announces Clinical Collaboration with Amgen to Study BBP-398, a Potentially Best-in-class SHP2 Inhibitor, in Combination with LUMAKRAS® (sotorasib) in Advanced Solid Tumors with the KRAS G12C Mutation

BridgeBio Pharma, Inc. today announced a non-exclusive clinical collaboration with Amgen Inc. (Amgen) to evaluate the combination of BBP-398.

January 13, 2022
·
6 min read
Business

Nephros Issues 2022 Shareholder Letter

Nephros, Inc today issued a 2022 letter to shareholders.

January 13, 2022
·
9 min read
Business

Vitalhub Announces Multi-Year Licensing Agreement with Stafford and Stoke-on-Trent Integrated Care Systems

VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce a multi-year licensing agreement of wholly-owned subsidiary Transforming Systems’ proprietary SHREWD Resilience and COVID-19 modules with Staffordshire and Stoke-on-Trent Integrated Care Systems (the “ICS” or Staffordshire and Stoke-on-Trent”).

January 13, 2022
·
5 min read